Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab/Tuvonralimab Combined With Nab-paclitaxel and Cisplatin as Neoadjuvant Therapy for Locally Advanced Cervical Cancer
NCT07876154Phase 2Recruiting
- Sponsor
- Xijing Hospital
- Start
- Sep 2025
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in Cervical Cancer (CC), sponsored by Xijing Hospital. Started Sep 2025; status: recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT07876154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07876154.